SSSteffi Schumacher

Steffi Schumacher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Steffi Schumacher has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Astrocyte‐Targeted connexin43 Hemichannel Inhibition Prevents Radiation‐Induced Energy Transporter Decrease in Neurons and Astrocytic proBDNF Transport to Synapses

    by Steffi Schumacher, Sara Neyt, Christian Vanhove, Lien De Schaepmeester, Robrecht Raedt, Katja Witschas, Luc Leybaert

    Radiation therapy is widely used for treating brain tumors but also comes with off‐target effects, including vascular blood–brain barrier (BBB) leakage occurring as an early event 24 h postirradiation. Here we investigated brain X‐irradiation (20 Gy) effects on the astrocyte‐neuronal axis starting from BBB endothelium and ending at synapses. Making use of immune‐characterization of brain slices isolated 24 h after irradiation of rodents, we found significantly decreased neuronal expression of GLUT3 glucose transporters and MCT2 monocarboxylate transporters in M1/S1 cortical areas, with no changes in astrocytic GLUT1 transporters. Pre‐irradiation animal treatment with the Cx43 hemichannel blocker TATGap19 targeting astrocytes completely prevented these neuronal alterations. Brain uptake of 18F‐deoxy‐glucose was decreased in the pre‐ and infra‐limbic cortex 24 h postirradiation, not in other cortical areas, and was prevented by TATGap19 treatment. Electro‐encephalographic recordings showed decreased power in delta, theta, beta, and gamma bands, most clearly in S1 cortex 24 h postirradiation. ProBDNF, a precursor of brain‐derived neurotrophic factor associated with negative neural effects, was significantly elevated 24 h postirradiation and accompanied by strong activation of its vesicular transport in astrocytes. In particular, proBDNF uptake in astrocytic endfeet at capillary endothelial cells and its VAMP3‐associated release at astrocytic extensions to tripartite synapses were both strongly increased and prevented by animal pretreatment with TATGap19. The present data show that astrocytes are a major target for radiotherapeutic intervention whereby Gap19 inhibition of the Cx43 hemichannel membrane leakage pathway prevents radiation‐induced alterations in brain glucose handling and activation of vesicular proBDNF transport to tripartite synapses that disturb neural functioning.

  • Open Access

    Inhibiting astrocyte connexin‐43 hemichannels blocks radiation‐induced vesicular VEGF‐A release and blood–brain barrier dysfunction

    by Steffi Schumacher, Hanane Tahiri, Pascal Ezan, Nathalie Rouach, Katja Witschas, Luc Leybaert

    Therapeutic brain irradiation with ionizing radiation exerts multiple side effects including barrier leakage that disturbs glial‐neuronal functioning and may affect cognition. Astrocytes contribute to barrier leakage by endfeet release of various vasoactive substances acting on capillary endothelial cells forming the barrier. Here, we investigated X‐ray effects on astrocytic vesicular transport in mice and determined whether interfering with astrocyte connexins affects radiation‐induced barrier leakage. We found that astrocytic VEGF‐A‐loaded VAMP3 vesicles drastically reorganize starting from 6 h post‐irradiation and move in a calcium‐ and Cx43‐dependent manner towards endfeet where VEGF‐A is released, provoking barrier leakage. Vesicular transport activation, VEGF‐A release and leakage 24 h post‐irradiation were all potently inhibited by astrocytic Cx43 KO, Cx43S255/262/279/282A (MK4) mutant mice and TATGap19 inhibition of Cx43 hemichannel opening. Astrocyte VEGF release is a major player in complications of brain irradiation, which can be mitigated by anti‐VEGF treatments. Targeting Cx43 hemichannels allows to prevent astrocyte VEGF release at an early stage after brain irradiation.


  • Open Access

    Targeting gliovascular connexins prevents inflammatory blood-brain barrier leakage and astrogliosis

    by Marijke De Bock, Maarten De Smet, Stijn Verwaerde, Hanane Tahiri, Steffi Schumacher, Valérie Van Haver, Katja Witschas, Christian Steinhäuser, Nathalie Rouach, Roosmarijn E. Vandenbroucke, et al.

    The blood-brain barrier is formed by capillary endothelial cells expressing connexin 37 (Cx37), Cx40, and Cx43 and is joined by closely apposed astrocytes expressing Cx43 and Cx30. We investigated whether connexin-targeting peptides could limit barrier leakage triggered by LPS-induced systemic inflammation in mice. Intraperitoneal LPS administration increased endothelial and astrocytic Cx43 expression; elevated TNF-α, IL-1β, IFN-γ, and IL-6 in plasma and IL-6 in the brain; and induced barrier leakage recorded over 24 hours. Barrier leakage was largely prevented by global Cx43 knockdown and Cx43/Cx30 double knockout in astrocytes, slightly diminished by endothelial Cx43 knockout, and not protected by global Cx30 knockout. Intravenous administration of Gap27 or Tat-Gap19 peptides just before LPS also prevented barrier leakage, and intravenously administered BAPTA-AM to chelate intracellular calcium was equally effective. Patch-clamp experiments demonstrated LPS-induced Cx43 hemichannel opening in endothelial cells, which was suppressed by Gap27, Gap19, and BAPTA. LPS additionally triggered astrogliosis that was prevented by intravenous Tat-Gap19 or BAPTA-AM. Cortically applied Tat-Gap19 or BAPTA-AM to primarily target astrocytes also strongly diminished barrier leakage. In vivo dye uptake and in vitro patch-clamp showed Cx43 hemichannel opening in astrocytes that was induced by IL-6 in a calcium-dependent manner. We conclude that targeting endothelial and astrocytic connexins is a powerful approach to limit barrier failure and astrogliosis.